

IMPORTANCE OF PYRIMIDINE NUCLEOTIDE SALVAGE PATHWAYS FOR DNA SYNTHESIS IN SKIN

NEIL W. DELAPP, PH.D., AND MARVIN A. KARASEK, PH.D.

Department of Dermatology, Stanford University School of Medicine, Stanford California, U.S.A.

Split-thickness rabbit skins were minced and incubated *in vitro* with radioactive precursors selected to measure *de novo* and salvage pathways for pyrimidine nucleotide synthesis. In this system, both the salvage precursors [^3H]thymidine and [^{14}C]cytidine were incorporated actively into skin DNA and only [^{14}C]cytidine into skin RNA. In contrast, the *de novo* precursor [^{14}C]orotic acid labeled skin RNA extensively but did not significantly label skin DNA. An unusually high ratio of specific activities of UMP:TMP in RNA was observed when [^{14}C]orotic acid was used as a nucleotide precursor.

Methotrexate effectively blocked thymidylate synthesis *de novo* but did not inhibit DNA synthesis as determined by [^3H]thymidine incorporation into DNA thymidylate residues or by [^{14}C]deoxycytidine incorporation into DNA deoxycytidylate residues. Azauridine inhibited labeling of RNA by [^{14}C]orotic acid to a greater extent than labeling of DNA by [^3H]thymidine.

These results suggest that in rabbit skin, cytidine nucleotides are utilized more effectively than uridine nucleotides for deoxypyrimidine biosynthesis, that DNA synthesis is primarily dependent upon salvage mechanisms to supply deoxypyrimidine nucleotides, and that inhibition of thymidylate synthesis by methotrexate does not inhibit DNA synthesis in this system.

The importance of salvage pathways for purine nucleotide biosynthesis in humans became strikingly apparent with the discovery of the Lesch-Nyhan syndrome in the mid 1960s [1]. This congenital neurologic disorder characterized by severe mental retardation and compulsive self-mutilation was shown to be associated with an almost complete

lack of the purine salvage enzyme hypoxanthine/guanine phosphoribosyltransferase, along with a dramatic increase in purine nucleotide biosynthesis *de novo* in afflicted individuals [1-3]. Observations of the Lesch-Nyhan syndrome suggested that salvage pathways for nucleic acid biosynthesis as well as a regulatory balance between salvage and *de novo* routes are of crucial importance in mammalian metabolism.

Figure 1 outlines the *de novo* and salvage pathways for pyrimidine nucleotide synthesis in mammalian tissues. The first structure formed in the *de novo* pathway (*open arrows*) having the characteristic pyrimidine ring is orotic acid. It may be metabolized further, as shown, to uridine and cytidine nucleotide constituents of RNA as well as to thymidine and deoxycytidine nucleotide constituents of DNA. Pyrimidine nucleotide components of nucleic acids may also be acquired via salvage pathways (*solid arrows*) by incorporation of the nucleosides uridine and cytidine and the deoxynucleosides thymidine, deoxycytidine, and deoxyuridine.

Newborn mouse skin has been shown to carry out *de novo* pyrimidine nucleotide biosynthesis *in vitro* as well as to possess salvage mechanisms for incorporation of deoxypyrimidine nucleosides into DNA [4,5]. Although a knowledge of the relative contributions of salvage and *de novo* pathways to skin DNA synthesis could be of considerable value in developing new methods of chemotherapy for proliferative skin diseases, such information is not available for skin [6]; however, there are reports on

Manuscript received August 22, 1975; in revised form December 15, 1975; accepted for publication December 16, 1975.

This study was supported by Grant AM 10332 of the National Institutes of Health, United States Public Health Service.

Presented in part at the 32nd Annual Meeting of the American Federation for Clinical Research, Atlantic City, New Jersey, May 3, 1975.

Reprint requests to: Dr. M. A. Karasek, Department of Dermatology, Stanford University School of Medicine, Stanford, California 94305.

Abbreviations:

CDP: cytidine-5'-diphosphate
CMP: cytidine-5'-monophosphate
CTP: cytidine-5'-triphosphate
DHF: dihydrofolic acid
dCDP: deoxycytidine-5'-diphosphate
dCMP: deoxycytidine-5'-monophosphate
dCTP: deoxycytidine-5'-triphosphate
dTDP: deoxythymidine-5'-diphosphate
dTMP: deoxythymidine-5'-monophosphate
dTTP: deoxythymidine-5'-triphosphate
dUDP: deoxyuridine-5'-diphosphate
dUMP: deoxyuridine-5'-monophosphate
MTX: methotrexate
THF: tetrahydrofolic acid
UDP: uridine-5'-diphosphate
UMP: uridine-5'-monophosphate
UTP: uridine-5'-triphosphate

maintaining the pH between 8.0 and 8.2. If deoxynucleosides were required, a further hydrolysis with 3 units of alkaline phosphatase for 2 hr at pH 8.2 was carried out. Following hydrolysis to either deoxynucleotides or deoxynucleosides, protein was precipitated by adjusting the pH to 2 with 2 N and 0.5 N HClO_4 , and the precipitate was removed by centrifugation after chilling on ice for 30 min.

To convert ribonucleotides to the free bases, alkaline hydrolysates were neutralized with 4 N HClO_4 . KClO_4 was removed by centrifugation after chilling on ice for 30 min, and the supernatant solutions were lyophilized to dryness. Residues were taken up in 1.2 ml of 70–72% HClO_4 and were boiled (100°C) for 1 hr. Hydrolysates were neutralized with KOH after dilution with 3 ml H_2O . KClO_4 was precipitated by chilling on ice for 30 min, and following centrifugation the supernatant solutions were lyophilized to dryness.

Chromatography of Ribonucleotides and Deoxyribonucleotides, Deoxyribonucleosides, and Free Bases

Charcoal columns 0.6×7.5 cm were washed with 0.1 N HCl , H_2O , charcoal eluant (ethanol: H_2O : NH_3 —125:122:3), H_2O , and 0.1 N HCl prior to use. Polyethyleneimine-impregnated cellulose thin-layer plates were washed and stored as described by Randerath and Randerath [13].

Alkaline hydrolysates containing ribonucleotides were adjusted to pH 2 and applied to prewashed charcoal columns which were then washed further with 200 ml H_2O followed by elution of ribonucleotides with 30 ml of charcoal eluant (see above). Eluted nucleotides were dried under vacuum and were dissolved in 0.3 ml H_2O . Aliquots (100 μl) were spotted on washed thin-layer plates and the plates were dipped in methanol for 15 min and dried prior to chromatography. Ribonucleotides were resolved by two-dimensional chromatography using the LiCl-HCOOH/NaCOOH procedure described by Colby and Edlin [14].

Purine and pyrimidine bases produced by strong acid hydrolysis of ribonucleotides were resolved on a 0.6×70 cm column of Bio-Gel P-2 [15].

Deoxynucleotides were applied to charcoal columns and eluted in the same way as described for ribonucleotides. Dried eluates were dissolved in 0.3 ml H_2O and 100 μl aliquots were applied to thin-layer plates. The plates were immersed in methanol for 5 min, dried, and chromatographed in 1 M LiCl saturated with boric acid (pH 4.5):ethanol—1:1 for resolution of the deoxynucleotides [16]. Deoxynucleosides were resolved into deoxypyrimidines and deoxypurines by column chromatography on Bio-Gel P-2 [15] without prior charcoal treatment.

Ribonucleotides and deoxyribonucleotides resolved by thin-layer chromatography were visualized under ultraviolet light. The nucleotides were marked, cut out of the plastic-backed plates, and were eluted from the cellulose with 0.1 N HCl at room temperature for 18 hr. Nucleotides were quantitated by ultraviolet absorption of the eluates at 260 and 280 nm. Compounds were identified by chromatographic position relative to known standards and by the ultraviolet absorption ratio of 280:260. After quantitation by ultraviolet absorption, eluates were dried under vacuum, dissolved in 0.5 ml H_2O , and were counted in Bray's solution in a Beckmann liquid scintillation spectrometer with a counting efficiency of 30% for ^3H and 60% for ^{14}C . Fractions collected from the Bio-Gel column (0.5 ml) were adjusted to 1.2 ml with H_2O , the ultraviolet absorption of each fraction at 260 nm was determined, and whole fractions were then counted in Bray's solution as above. Pyrimidine bases and deoxy-

pyrimidine nucleosides were quantitated by the total absorbancy at 260 nm of Bio-Gel chromatographic peaks.

RESULTS

Time-Dependence of [^3H]Thymidine Incorporation into DNA

Figure 2 shows the time-dependent incorporation of [^3H]thymidine into rabbit skin DNA. Thymidine incorporation was linear for 3 hr and reached a plateau at 4 hr.

DNA and RNA Synthesis in Skin and Liver

Table I compares [^3H]thymidine and [^{14}C]orotic acid incorporation over a 3-hr interval into DNA and RNA of newborn mouse skin, newborn mouse liver, and adult rabbit skin. [^3H]Thymidine was actively incorporated into newborn mouse skin DNA and relatively little labeling of RNA preparations was observed. Although [^{14}C]orotic acid actively labeled newborn mouse skin RNA, very little labeling of skin DNA was obtained with this precursor. In contrast to skin under the same conditions in vitro, newborn mouse liver DNA and RNA were labeled when [^{14}C]orotic acid was used as a precursor. The difference between newborn mouse skin and liver with respect to [^{14}C]orotic acid labeling of DNA was more extensive than the difference in [^3H]thymidine incorporation between these two tissues. Like newborn mouse skin, rabbit skin incorporated [^3H]thymidine into DNA and [^{14}C]orotic acid into RNA, but did not exhibit substantial labeling of DNA by [^{14}C]orotate.




FIG. 2. Time dependence of [^3H]thymidine incorporation in vitro into rabbit skin DNA. Each point represents the mean value from two incubations.

TABLE I. Incorporation of [^3H]thymidine and [^{14}C]orotic acid into skin and liver nucleic acids in vitro

Tissue	Specific activity (cpm/ μmole of DNA or RNA phosphate)			
	DNA		RNA	
	^3H	^{14}C	^3H	^{14}C
Newborn mouse liver	14,046	1,650	334	6,621
Newborn mouse skin	5,298	38	175	4,552
Adult rabbit skin	7,152	56	242	14,758

To determine whether the light labeling of rabbit skin DNA by [^{14}C]orotate represented actual incorporation into DNA at a low level or a small amount of RNA contamination of the DNA preparations, constituent deoxynucleosides were isolated by Bio-Gel P-2 column chromatography. Figure 3a shows the incorporation of [^3H]thymidine and [^{14}C]orotic acid into the deoxypyrimidine nucleosides (thymidine plus deoxycytidine) of rabbit skin DNA. A large peak of [^3H]thymidine incorporation (*open triangles*) was obtained along with a very small peak due to labeling of DNA by [^{14}C]orotate (*closed circles*). Figure 3b shows the extensive incorporation of [^{14}C]orotate into the deoxypyrimidine nucleosides of newborn mouse liver DNA

(*closed circles*). No labeling of the deoxypurines was observed with either [^3H]thymidine or [^{14}C]orotic acid in liver or skin.

Incorporation of [^{14}C]Cytidine into Skin DNA and RNA

In contrast to the low level of labeling of DNA by orotic acid as shown in Figure 3b, the incorporation of cytidine into DNA was more extensive (Fig. 3c). Although the specific activity of [^{14}C]cytidine in these studies was lower than [^{14}C]orotic acid, the differences in uptake of isotopes was marked. Table II illustrates the magnitude of these differences. As shown in this Table, cytidine labels DNA 78-fold as extensively as orotic acid. Although [^{14}C]cytidine was incorporated into both UMP and CMP residues of RNA, orotic acid incorporation into RNA resulted in a relative specific activity of UMP 41 times that of CMP.

Incorporation of Nucleotide Precursors into Skin and Liver RNA and DNA

Table III compares the incorporation of labeled pyrimidine nucleotide precursors into rabbit skin and newborn mouse liver DNA and RNA. [^3H]Thymidine was omitted from these incubations.

TABLE II. Incorporation of [^3H]thymidine and [^{14}C]orotic acid into rabbit skin pyrimidine nucleotides of RNA and deoxypyrimidine nucleosides of DNA

Precursor	Relative specific activities			
	RNA ^{14}C		DNA Tdr + CdR	
	UMP	CMP	^3H	^{14}C
[^{14}C]Orotic acid + [^3H]thymidine	1,584	38	87	1
[^{14}C]Cytidine + [^3H]thymidine	4,226	15,982	122	78

TABLE III. Incorporation of [^{14}C]labeled pyrimidine nucleotide precursors into rabbit skin and newborn mouse liver nucleic acids

Tissue	Precursor	Relative specific activities		
		RNA		DNA
		UMP	CMP	CdR + Tdr
Rabbit skin	[^{14}C]Orotate ^a	10,226	118	2
	[^{14}C]Uridine	28,167	298	9
	[^{14}C]Cytidine	8,190	30,323	90
Mouse liver	[^{14}C]Orotate	736	122	104
	[^{14}C]Cytidine	983	402	300

^a [^{14}C]Orotic acid was present in this experiment at 10 $\mu\text{Ci/ml}$ resulting in a medium concentration 5-fold higher than that used for [^{14}C]cytidine or [^{14}C]uridine. In the mouse liver experiment, orotic acid concentration was the same as that for cytidine.




FIG. 3. Incorporation into DNA deoxypyrimidine nucleotides. a: [^3H]Thymidine and [^{14}C]orotic acid into rabbit skin. b: [^{14}C]Orotic acid into newborn mouse liver. c: [^3H]Thymidine and [^{14}C]cytidine into rabbit skin. Peak I (fraction numbers 6-9) represents a small amount of higher-molecular-weight nucleic acids and proteins; peak II (fraction numbers 17-20) represents isolated deoxypyrimidines (Tdr plus CdR); peak III (fraction numbers 21-25) represents deoxypurines (AdR plus GdR). \square — \square = Absorbance at 260 nm; Δ — Δ = ^3H -cpm; \bullet — \bullet = ^{14}C -cpm.

TABLE IV. *Effect of hydroxyurea and MTX on labeled deoxynucleoside incorporation into rabbit skin DNA*

Inhibitor	Precursor	Specific activity ^a (cpm/μmole deoxynucleotide)		
			dTMP	dCMP
<i>Hydroxyurea</i> (100 μM)				
Ex. #1	[³ H]TdR	Control	27,460 ± 130	—
		Treated	15,306 ± 150 (.005 < p < .01) ^b	—
Ex. #2	[³ H]TdR	Control	13,619 ± 640	—
		Treated	7,531 ± 266 (.001 < p < .005)	—
<i>Methotrexate</i> (14 μM)				
Ex. #1	[³ H]TdR	Control	17,423 ± 964	—
		Treated	18,462 ± 2687 (p > 0.5)	—
Ex. #2	[¹⁴ C]CdR	Control	570 ± 88	3,187 ± 109
		Treated	73 ± 52 (.001 < p < .005)	2,921 ± 253 (.05 < p < 0.1)
Ex. #3	[¹⁴ C]CdR	Control	1,918 ± 35	9,567 ± 923
		Treated	315 ± 68 (p < .001)	9,707 ± 697 (p > 0.5)

^a Specific activities are the mean values plus or minus standard deviation of 3 skin samples each for controls and inhibitor-treated preparations.

^b p values calculated using Students *t*-test for paired data.

TABLE V. *Effect of azauridine on [¹⁴C]orotic acid incorporation into rabbit skin RNA and upon [³H]thymidine incorporation into skin DNA*

Azauridine concentration		Specific activity ^a	
		RNA cpm/O.D. 260	DNA cpm/ μ mole
		Cytosine plus uracil	dTMP
Ex. 1. 5 \times 10 ⁻⁵ M	Control	3,113 \pm 604	18,541 \pm 1,410
	Treated	1,760 \pm 193 (.05 < p < 0.1) ^b	19,012 \pm 1,805 (p > 0.5)
Ex. 2. 5 \times 10 ⁻⁴ M	Control	3,195 \pm 278	15,708 \pm 450
	Treated	798 \pm 92 (.005 < p < .01)	12,525 \pm 1,086 (.025 < p < .05)

^a Specific activities are the mean plus or minus standard deviation of 3 skin samples each for control and inhibitor-treated preparations.

^b p values calculated using Students *t*-test for paired data.

tions to rule out the possibility that thymidine might exert an inhibitory effect on DNA synthesis de novo as demonstrated by Cannon and Breitman [17]. In contrast to skin, newborn mouse liver exhibited a 3-fold difference in relative specific activities of deoxypyrimidines when cytidine and orotic acid were used as precursors. Incorporation of [¹⁴C]orotic acid into newborn mouse liver and rabbit skin RNA was also different with respect to the relative labeling of uridylylate and cytidylylate residues. Labeling of newborn mouse liver RNA with [¹⁴C]orotic acid resulted in a UMP:TMP ratio of relative specific activities of 6:1 compared to

86:1 for skin RNA. Similarly, [¹⁴C]uridine incorporation into skin resulted in more extensive labeling of UMP than of CMP residues of RNA and labeled DNA to $\frac{1}{10}$ the extent of [¹⁴C]cytidine.

Effect of Hydroxyurea, Methotrexate, and Azauridine on Skin DNA and RNA Synthesis

Table IV shows the effects of hydroxyurea and MTX on incorporation of deoxynucleosides into rabbit skin DNA. Hydroxyurea, an inhibitor of skin ribonucleotide reductase (unpublished observations), caused a significant 44 to 45% inhibition of [³H]thymidine incorporation into skin DNA.